Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 3:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 3,889 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: no drug Clear all
Completed Phase 4 Interventional Results available

Intervention to Promote Weight Loss in Latinas At-risk for Diabetes

NCT02088034
View directory record Official record
Conditions
Diabetes
Interventions
Promotora-led Intervention, Metformin Therapy, Usual Care
Behavioral · Drug · Other
Lead sponsor
Temple University
Other
Eligibility
20 Years to 75 Years · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 14, 2026, 3:57 PM EDT
Active, not recruiting Phase 1 Interventional

CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

NCT03572764
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
CPX-351, Research skin biopsy, Research blood draw, Research bone marrow aspirate
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Tampa, Florida • St Louis, Missouri • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 14, 2026, 3:57 PM EDT
Recruiting Not applicable Interventional

VIBRating vs Traditional Therapy for Treatment of ENTry Dyspareunia

NCT06840314
View directory record Official record
Conditions
Genito-Pelvic Pain/Penetration Disorder, Dyspareunia, Vaginismus, Pelvic Pain, Vestibulodynia, Vulvodynia (Chronic Vulvar Pain)
Interventions
Pelvic floor therapy
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 14, 2026, 3:57 PM EDT
Completed Phase 3 Interventional Results available

Study of 0416 Ointment in the Treatment of Atopic Dermatitis

NCT01053247
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
0416, Vehicle of 0416 test product, tacrolimus ointment 0.1%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Oct 14, 2026, 3:57 PM EDT
Not yet recruiting Phase 1 Interventional

Psilocybin After Trauma Surgery for Pain

NCT07406828
View directory record Official record
Conditions
Pain Management, Postoperative Pain
Interventions
Psilocybin (Usona Institute), Postoperative analgesia
Drug
Lead sponsor
Trent Emerick
Other
Eligibility
25 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 14, 2026, 3:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin

NCT00630734
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia
Interventions
Pravastatin, Darunavir, Ritonavir, Washout
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 14, 2026, 3:57 PM EDT
Active, not recruiting No phase listed Observational

Postpartum Home Visiting (HEART at Home)

NCT07833904
View directory record Official record
Conditions
Hypertensive Disorders of Pregnancy (HDP)
Interventions
HEART at Home
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 14, 2026, 3:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Titration of Intravenous Hydromorphone

NCT01892709
View directory record Official record
Conditions
Acute Severe Pain
Interventions
Hydromorphone
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 14, 2026, 3:57 PM EDT
Completed Phase 2 Interventional Results available

Polypill in Acute Coronary Syndrome

NCT05514938
View directory record Official record
Conditions
Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
Interventions
Polypill, Usual Care (individual medications prescribed by primary cardiologist)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 14, 2026, 3:57 PM EDT
Completed Phase 1 Interventional

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

NCT03441048
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Lintuzumab-Ac-225, Cladribine, Cytarabine, Mitoxantrone, G-CSF
Biological · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Milwuakee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 14, 2026, 3:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®

NCT00920647
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Control, Idursulfase IT (1 mg), Idursulfase IT (10 mg), Idursulfase IT (30 mg)
Other · Drug
Lead sponsor
Shire
Industry
Eligibility
3 Years to 18 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 14, 2026, 3:57 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

NCT02605915
View directory record Official record
Conditions
HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer, Locally Advanced or Early Breast Cancer
Interventions
Atezolizumab, Carboplatin, Docetaxel, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Joliet, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 14, 2026, 3:57 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

NCT04157517
View directory record Official record
Conditions
Neoplasms, Melanoma
Interventions
Modakafusp Alfa, Pembrolizumab
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
15
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 14, 2026, 3:57 PM EDT
Recruiting Phase 4 Interventional

Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)

NCT07672015
View directory record Official record
Conditions
Opioid Consumption, Postoperative
Interventions
Suzetrigine, Standard Care (in control arm)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 14, 2026, 3:57 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Poke and a Placebo

NCT04497220
View directory record Official record
Conditions
Anesthesia
Interventions
Negative Connotation Langauge, Positive Connotation Language
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 14, 2026, 3:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cardiovascular Effects of Adderall in Healthy Adults.

NCT02979327
View directory record Official record
Conditions
Hemodynamics, Cardiovascular System
Interventions
Adderall capsule, Placebo capsule
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 14, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Results available

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas

NCT02171260
View directory record Official record
Conditions
Pediatrics, Solid Tumors
Interventions
Eribulin Mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 14, 2026, 3:57 PM EDT
Completed Not applicable Interventional

Modified Atkins Diet Plus KetoCal for Adult Epilepsy

NCT01834482
View directory record Official record
Conditions
Epilepsy, Seizure, Medically Resistant Epilepsy, Medically Resistant Seizures
Interventions
Modified Atkins diet, KetoCal
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 14, 2026, 3:57 PM EDT
Completed Not applicable Interventional Results available

Mindfulness-Based Relapse Prevention to Improve Medication Assisted Treatment Adherence and Drug-use Outcomes for Opioid Use Disorder

NCT05042388
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Mindfulness-Based Relapse Prevention - Rolling Admission (MBRP-RA), Treatment-As-Usual
Behavioral
Lead sponsor
West Chester University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
West Chester, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 14, 2026, 3:57 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The HOPE Study: Characterizing Patients With Hepatitis B and C

NCT02995252
View directory record Official record
Conditions
Hepatitis B， Chronic, Hepatitis C
Interventions
Blood draws, Tenofovir Alafenamide, Knowledge Index Questionnaire, Liver transient elastography (FibroScan), Liver Biopsy
Other · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 99 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2034
U.S. locations
2
States / cities
Baltimore, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 14, 2026, 3:57 PM EDT
Completed Phase 3 Interventional

ACTIV-3: Therapeutics for Inpatients With COVID-19

NCT04501978
View directory record Official record
Conditions
Covid19
Interventions
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
98
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 14, 2026, 3:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Clinical Evaluation of the OrthoPAT Advance System

NCT01756976
View directory record Official record
Conditions
Transmission, Blood, Recipient/Donor
Interventions
OrthoPat Advance
Device
Lead sponsor
Haemonetics Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 14, 2026, 3:57 PM EDT
Not listed Phase 2 Interventional

A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma

NCT00931840
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
EZN-2208, Cetuximab and Irinotecan
Drug
Lead sponsor
Enzon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
35
States / cities
Tucson, Arizona • Alhambra, California • Bakersfield, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 14, 2026, 3:57 PM EDT
Completed Phase 2 Interventional Results available

Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention

NCT04966507
View directory record Official record
Conditions
Gonorrhea
Interventions
Listerine Antiseptic Mouthwash Product, Biotene Mouthwash
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 14, 2026, 3:57 PM EDT